The Bone Crisis Nobody Talks About Until It Happens
Osteoporosis — a disease of reduced bone mineral density and deteriorating bone microarchitecture — affects an estimated 10 million Americans, with another 44 million having low bone mass (osteopenia) placing them at elevated fracture risk. One in two women and one in four men over 50 will experience an osteoporosis-related fracture in their remaining lifetime. Hip fractures in particular carry a 20–30% one-year mortality rate in older adults — making bone health a genuine longevity issue, not merely a “quality of life” concern.
The good news: hormone therapy is one of the most powerful tools available for bone density preservation, and its benefits are measurable, clinically significant, and well-documented across decades of research.
How Sex Hormones Protect Bone
Estrogen is the primary protective hormone for bone in both women and men. Estrogen receptors on osteoclasts (bone-resorbing cells) receive inhibitory signals from estrogen — suppressing bone resorption. When estrogen declines at menopause, this brake on osteoclast activity is released, and bone resorption accelerates dramatically. Women can lose 2–3% of bone mineral density per year in the first 5–10 years after menopause — a bone loss rate that cannot be compensated by diet and exercise alone.
Testosterone supports bone density through both direct androgen receptor activity on osteoblasts (bone-building cells) and indirectly through aromatization to estradiol in bone tissue. Men with hypogonadism consistently show lower bone mineral density than age-matched eugonadal men, and TRT has been shown to significantly improve BMD in hypogonadal men — particularly at the lumbar spine and femoral neck, the most clinically relevant fracture sites.
DHEA contributes to bone health through conversion to both androgens and estrogens in bone tissue. Low DHEA-S is independently associated with lower bone mineral density in older adults of both sexes.
HRT and Osteoporosis Prevention: The Evidence
The Women’s Health Initiative, despite its controversies regarding cardiovascular and breast risk, unambiguously demonstrated significant fracture reduction with HRT: 34% reduction in hip fractures, 24% reduction in vertebral fractures, and 24% reduction in all fractures combined. Subsequent studies using transdermal estrogen and bioidentical progesterone have confirmed these benefits with favorable safety profiles.
For women at high fracture risk who discontinue HRT, bisphosphonate therapy (e.g., alendronate, risedronate) is often recommended as a bridge — but HRT remains the most physiologically comprehensive intervention, addressing not just bone but the full spectrum of menopausal health domains simultaneously.
Monitoring Bone Health at Multigen Wellness
Patients starting or on hormone therapy who are 50 or older, or who have significant risk factors for osteoporosis, are recommended to undergo DEXA scanning for baseline and interval bone mineral density measurement. Results guide both hormone dosing discussions and the decision to add pharmacological bone protection if needed.
Hormone therapy is one of the most powerful investments in your skeletal longevity. Call Multigen Wellness at (800) 259-0015 to discuss bone health as part of your comprehensive hormone evaluation.